We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Benign Tissue Structural Features Predict Risk of Prostate Cancer Recurrence Following Surgery

By LabMedica International staff writers
Posted on 18 Jul 2016
A preliminary study found that evaluation of a collection of structural features observed in normal tissues surrounding a prostate tumor was a better predictor of risk of recurrence of the cancer following surgical removal of the tumor by radical prostatectomy (RP).

Gleason scoring represents the standard for diagnosis of prostate cancer (PCa) and assessment of prognosis following RP. A Gleason score is given to prostate cancer based upon its microscopic appearance. Cancers with a higher Gleason score are more aggressive and have a worse prognosis. The method is based on H&E-stained immunohistochemistry sections using antibody 34betaE12, reactive against basal cell–specific high-molecular-weight cytokeratins.

Investigators at Case Western Reserve University (Cleveland, OH, USA) and Johns Hopkins University (Baltimore, MD, USA) suggested that Gleason scoring did not account for structural patterns in neighboring normal-appearing benign fields that might be more predictive of disease recurrence.

To examine the predictive value of benign tissue structural features, the investigators analyzed records from 70 patients who had undergone RPs from 2000 to 2004 with up to 14 years follow-up. The investigators digitized images of the resected prostate specimens and analyzed the tumor regions and surrounding tissues that appeared to be benign. The top 10 features identified as most predictive of recurrence within both the benign and cancerous regions were combined into a 10-feature signature (tumor plus adjacent benign signature or TABS). Computer-extracted nuclear shape and architectural features from cancerous regions, adjacent benign fields, and TABS were evaluated with various statistical tools.

Among the patient group, 22 experienced prostate cancer recurrence in the form of biochemical recurrence (increase in PSA levels), metastasis, or death. In all cases tumor-adjacent benign field features were predictive, with tumor-field nuclear shape descriptors and benign-field local nuclear arrangement being the most useful features found for TABS. Combining TABS with a Gleason sum further improved prediction of recurrence. Overall, nuclear shape and architecture in the benign-looking tissue were greater predictors of recurrence than features found in the tumor.

"In a sense, this study is validating what a lot of people think regarding these cancers - that there is a field effect, as if the tumor has hard-to-see tentacles that can affect the patient and outcomes," said senior author Dr. Anant Madabhushi, professor of biomedical engineering at Case Western Reserve University. "There is a clear path to a clinical/translational test. There is no destruction of tissue - nothing to stop us from analyzing the images and specimens and coming up with a risk score."

The study was published in the June 16, 2016, online edition of the journal European Urology Focus.

Related Links:
Case Western Reserve University
Johns Hopkins University

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centromere B Assay
Centromere B Test
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.